The decline of export is hard to change domestic API enterprises seeking transformation

According to the data from the Ministry of industry and information technology, in 2012, the growth rate of the overall fixed asset investment in China's pharmaceutical industry increased significantly year on year, which exceeded the growth rate of the industry's total output value and total assets, showing a significant expansion trend According to the statistics of the chamber of Commerce of medical insurance, from January to April this year, there were 6812 enterprises engaged in the export of APIs in China, an increase of 116 compared with the same period in 2012 In the new GMP transformation process, such rapid fixed asset investment is very easy to cause the problem of overcapacity in API manufacturing industry with relatively low technology content, and then reduce the overall profits of the industry, resulting in vicious competition, which is a common dilemma faced by many API enterprises at present In 2012, there was a negative growth in the profits of API industry, which is rare in recent years The main reason for the decline in profits is that the ability to digest environmental protection costs is not high and the environmental protection standards have been raised too fast On the one hand, all costs are rising, on the other hand, terminal drug prices are falling, which brings great difficulties to API enterprises Unless the enterprises have strong bargaining power, there are not many such API products at present The RMB exchange rate is still an important factor restricting the development of enterprises The increasing appreciation of RMB means the increasing export pressure of bulk APIs and intermediates with low added value The continuous appreciation of RMB exchange rate has seriously affected the export of enterprises The advantage of API export in price competition in China is gradually lost, which also forms a certain pressure on the operation of export enterprises Relevant API research report market prospect analysis and investment development of China's API and preparation industry 2014-2017 market prospect analysis and Investment Development Planning Research Report of China's API industry 2014-2020 market investigation and investment value analysis research of API industry 2014-2020 market investigation and investment value analysis research of API industry 2014-2020 Research Report 2013-2016 in-depth market survey and investment strategy research and analysis of API industry in Hefei, China more pharmaceutical industry analysis with the implementation of national policies and measures to support foreign trade development, will help enterprises accelerate transformation and upgrading, further improve their comprehensive competitive advantage, and ease current difficulties In general, China's API export will move forward in 2013 If China's API can maintain its existing international market share and expand, and considering the price factor, the annual export is expected to achieve 8-10% growth.